Drug Profile

KSB 302

Alternative Names: CBF-BS2; KSB302

Latest Information Update: 14 Jun 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator KS Biomedix Holdings
Class Disease-modifying antirheumatics
Mechanism of Action Glucose-6-phosphate dehydrogenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Rheumatoid arthritis

Most Recent Events

14 Jun 2002 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (PO)
24 May 2001 A phase IIb trial in Europe of KSB 302 has commenced
23 Aug 2000 A study in rheumatoid arthritis patients has been added to the adverse events and therapeutic trials sections

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com